Rinvoq (Upadacitinib) for Rheumatoid Arthritis

Overview

Rinvoq is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for treating moderate to severe rheumatoid arthritis in adults 18 years and older who have not responded to Methotrexate. Rinvoq may be prescribed alone or with Methotrexate. Rinvoq is also known by its drug name, Upadacitinib.

Rinvoq is a Janus kinase inhibitor. Rinvoq is believed to work by blocking Janus kinase enzymes which lead to inflammation for people with rheumatoid arthritis.

How do I take it?

Rinvoq is taken once a day.

Rinvoq comes in extended-release tablet form.

Side effects

The FDA-approved label for Rinvoq lists common side effects including upper respiratory infections, fever, nausea, and cough.

Rare but serious side effects listed for Rinvoq can include life-threatening infections, blood clots, liver problems, lymphomas, tuberculosis, and fetal harm in pregnant women.

For more details about this treatment, visit:

Rinvoq - AbbVie

www.rinvoq.com